PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1427

Yeah, same @Deebo.

Jakjazz, I think the fancy answer to this is that in evolutionary terms, canines are quite a lot closer to humans than rodents, and therefore their biological systems - including their mTOR signalling system- is more similar to our own, and this is why PAA chose to develop the mpl tablet for canines first and use that tablet then in human trials - so this is why they decided to give the MND trial a dual use as an MND trial and also a tolerability and pharmocokinetic trial for human cancer, and other uses. . In fact in cancer research, this has been the trend in recent years, going from lab rodent to canine to human. Cheers